Ember Financial Statements From 2010 to 2024

EMBT Stock  USD 0.0001  0.00  0.00%   
Ember Therapeutics financial statements provide useful quarterly and yearly information to potential Ember Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ember Therapeutics financial statements helps investors assess Ember Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ember Therapeutics' valuation are summarized below:
Ember Therapeutics does not presently have any fundamental signals for analysis.
Check Ember Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ember main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Ember financial statements analysis is a perfect complement when working with Ember Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Ember Therapeutics Technical models . Check out the analysis of Ember Therapeutics Correlation against competitors.

Ember Current Liabilities Analysis

Ember Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Current Ember Therapeutics Current Liabilities

    
  25.3 M  
Most of Ember Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ember Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition
In accordance with the recently published financial statements, Ember Therapeutics has a Current Liabilities of 25.3 M. This is 98.56% lower than that of the sector and 95.34% lower than that of the Current Liabilities industry. The current liabilities for all United States stocks is 99.68% higher than that of the company.

Ember Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ember Therapeutics's current stock value. Our valuation model uses many indicators to compare Ember Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ember Therapeutics competition to find correlations between indicators driving Ember Therapeutics's intrinsic value. More Info.
Ember Therapeutics is rated below average in book value per share category among related companies. It is rated below average in current asset category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Ember Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ember Therapeutics' Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ember Therapeutics' earnings, one of the primary drivers of an investment's value.

About Ember Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Ember Therapeutics income statement, its balance sheet, and the statement of cash flows. Ember Therapeutics investors use historical funamental indicators, such as Ember Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ember Therapeutics investors may use each financial statement separately, they are all related. The changes in Ember Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ember Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ember Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ember Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York. Ember Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ember Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ember Therapeutics' short interest history, or implied volatility extrapolated from Ember Therapeutics options trading.

Pair Trading with Ember Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ember Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ember Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Ember Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ember Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ember Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ember Therapeutics to buy it.
The correlation of Ember Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ember Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ember Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ember Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out the analysis of Ember Therapeutics Correlation against competitors.
Note that the Ember Therapeutics information on this page should be used as a complementary analysis to other Ember Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Ember Pink Sheet analysis

When running Ember Therapeutics' price analysis, check to measure Ember Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ember Therapeutics is operating at the current time. Most of Ember Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ember Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ember Therapeutics' price. Additionally, you may evaluate how the addition of Ember Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Please note, there is a significant difference between Ember Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ember Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ember Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.